Presentation is loading. Please wait.

Presentation is loading. Please wait.

A Prospective Observational Study to Evaluate a Cytomegalovirus (CMV)-Specific Enzyme-Linked Immunospot (Elispot) Assay in Allogeneic Hematopoietic Cell.

Published bySonny Tan Modified over 6 years ago

Similar presentations

Presentation on theme: "A Prospective Observational Study to Evaluate a Cytomegalovirus (CMV)-Specific Enzyme-Linked Immunospot (Elispot) Assay in Allogeneic Hematopoietic Cell."— Presentation transcript:

1 A Prospective Observational Study to Evaluate a Cytomegalovirus (CMV)-Specific Enzyme-Linked Immunospot (Elispot) Assay in Allogeneic Hematopoietic Cell Transplant (Allo-HCT) Recipients: The REACT Study  Ella J. Ariza-Heredia, Dimpy P. Shah, Drew J. Winston, Scott D. Rowley, Kathleen M. Mullane, Pranatharthi Chandrasekar, Robin K. Avery, Parameswaran Hari, Karl S. Peggs, Deepali Kumar, Rajneesh Nath, Per T. Ljungman, Sherif B. Mossad, Sanjeet S. Dadwal, William Cruikshank, Firas El Chaer, Roy F. Chemaly  Biology of Blood and Marrow Transplantation  Volume 23, Issue 3, Pages S46-S47 (March 2017) DOI: /j.bbmt Copyright © Terms and Conditions

2 Figure 1 % of patients with first reactivation.
Biology of Blood and Marrow Transplantation  , S46-S47DOI: ( /j.bbmt ) Copyright © Terms and Conditions

3 Figure 2 Median T-SPOT response.
Biology of Blood and Marrow Transplantation  , S46-S47DOI: ( /j.bbmt ) Copyright © Terms and Conditions

4 Figure 3 First Reaction vs Median T-SPOT Reconstitution.
Biology of Blood and Marrow Transplantation  , S46-S47DOI: ( /j.bbmt ) Copyright © Terms and Conditions

Download ppt "A Prospective Observational Study to Evaluate a Cytomegalovirus (CMV)-Specific Enzyme-Linked Immunospot (Elispot) Assay in Allogeneic Hematopoietic Cell."

Similar presentations

Galactomannan Antigen Enzyme-Linked Immunosorbent Assay for Diagnosis of Invasive Aspergillosis after Hematopoietic Stem Cell Transplantation  Patrick.

Galactomannan Antigen Enzyme-Linked Immunosorbent Assay for Diagnosis of Invasive Aspergillosis after Hematopoietic Stem Cell Transplantation  Patrick.
Cytomegalovirus Status and the Outcome of T Cell–Replete Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation  Frans M. Verduyn Lunel,

Cytomegalovirus Status and the Outcome of T Cell–Replete Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation  Frans M. Verduyn Lunel,
Trend, Risk Factors and Outcome of Thrombotic Microangiopathy in Pediatric Hematopoietic Stem Cell Transplant Recipients: A Multi-Institutional Review 

Trend, Risk Factors and Outcome of Thrombotic Microangiopathy in Pediatric Hematopoietic Stem Cell Transplant Recipients: A Multi-Institutional Review 
Hypertension and Diabetes Mellitus in Adult and Pediatric Survivors of Allogeneic Hematopoietic Cell Transplantation  Navneet S. Majhail, MD, MS, Tejo.

Hypertension and Diabetes Mellitus in Adult and Pediatric Survivors of Allogeneic Hematopoietic Cell Transplantation  Navneet S. Majhail, MD, MS, Tejo.
How to Treat MDS without Stem Cell Transplantation

How to Treat MDS without Stem Cell Transplantation
Allogeneic Hematopoietic Cell Transplantation May Alleviate the Negative Prognostic Impact of Monosomal and Complex Karyotypes on Patients with Acute.

Allogeneic Hematopoietic Cell Transplantation May Alleviate the Negative Prognostic Impact of Monosomal and Complex Karyotypes on Patients with Acute.
Vaccination of Children following Allogeneic Stem Cell Transplantation

Vaccination of Children following Allogeneic Stem Cell Transplantation
Hematopoietic Cell Transplantation Provides Durable Disease Control in Patients with Double-Hit Lymphoma  Taewoong Choi, Murali K. Kodali, Wen-Kai Weng 

Hematopoietic Cell Transplantation Provides Durable Disease Control in Patients with Double-Hit Lymphoma  Taewoong Choi, Murali K. Kodali, Wen-Kai Weng 
Reduced-Intensity Conditioning Hematopoietic Cell Transplantation Is an Effective Treatment for Patients with SLAM-Associated Protein Deficiency/X-linked.

Reduced-Intensity Conditioning Hematopoietic Cell Transplantation Is an Effective Treatment for Patients with SLAM-Associated Protein Deficiency/X-linked.
Continuous Intravenous Immunoglobulin and Platelet Infusion in Allogeneic Stem Cell Transplant Patients with Allo-Immune Thrombocytopenia  Katerina Ancevski,

Continuous Intravenous Immunoglobulin and Platelet Infusion in Allogeneic Stem Cell Transplant Patients with Allo-Immune Thrombocytopenia  Katerina Ancevski,
Richard Gopez Ancheta, MD, Carol Burian, CCRP, William E

Richard Gopez Ancheta, MD, Carol Burian, CCRP, William E
Allogeneic Stem Cell Transplantation in Myelofibrosis

Allogeneic Stem Cell Transplantation in Myelofibrosis
Predictive Value of Pre-Transplant PET/CT Scan before Autologous Stem Cell Transplant in Mantle Cell Lymphoma  Brian Hess, MD, Kathryn Trinkaus, Ph.D.,

Predictive Value of Pre-Transplant PET/CT Scan before Autologous Stem Cell Transplant in Mantle Cell Lymphoma  Brian Hess, MD, Kathryn Trinkaus, Ph.D.,
Allogeneic Hematopoietic Cell Transplantation (HCT) Results in Better Time to Next Therapy (TTNT) Than Chemotherapy (CT) in Chronic Lymphocytic Leukemia.

Allogeneic Hematopoietic Cell Transplantation (HCT) Results in Better Time to Next Therapy (TTNT) Than Chemotherapy (CT) in Chronic Lymphocytic Leukemia.
Vancomycin-Resistant Enterococcus (VRE) Colonization and Blood Stream Infection (BSI): Prevalence, Risk Factors, and Impact on Early Clinical Outcomes.

Vancomycin-Resistant Enterococcus (VRE) Colonization and Blood Stream Infection (BSI): Prevalence, Risk Factors, and Impact on Early Clinical Outcomes.
Hematopoietic Cell Transplantation with and without Sorafenib Maintenance for Patients with FLT3-ITD Acute Myeloid Leukemia in CR1  Andrew M. Brunner,

Hematopoietic Cell Transplantation with and without Sorafenib Maintenance for Patients with FLT3-ITD Acute Myeloid Leukemia in CR1  Andrew M. Brunner,
Efficacy of a Viral Load-Based, Risk-Adapted, Preemptive Treatment Strategy for Prevention of Cytomegalovirus Disease after Hematopoietic Cell Transplantation 

Efficacy of a Viral Load-Based, Risk-Adapted, Preemptive Treatment Strategy for Prevention of Cytomegalovirus Disease after Hematopoietic Cell Transplantation 
Biology of Blood and Marrow Transplantation

Biology of Blood and Marrow Transplantation
Optimizing Data Collection for Long-Term Follow-Up after Hematopoietic Stem Cell Transplant  Jaskiran Kaur, Madhu Ragupathi, Alysa Pleiner, Luda Kushner,

Optimizing Data Collection for Long-Term Follow-Up after Hematopoietic Stem Cell Transplant  Jaskiran Kaur, Madhu Ragupathi, Alysa Pleiner, Luda Kushner,
Carbon Monoxide Diffusion Capacity: How Low Can You Go for Hematopoietic Cell Transplantation Eligibility?  Jason W. Chien, Keith M. Sullivan  Biology.

Carbon Monoxide Diffusion Capacity: How Low Can You Go for Hematopoietic Cell Transplantation Eligibility?  Jason W. Chien, Keith M. Sullivan  Biology.

Similar presentations

Ads by Google